(S)-Crizotinib

• UNSPSC Description:

  (S)-Crizotinib is a potent and selective MTH1 (mutT homologue) inhibitor with an IC50 of 330 nM. (S)-Crizotinib disrupts nucleotide pool homeostasis via MTH1 inhibition, induces an increase in DNA single strand breaks, activates DNA repair in human colon carcinoma cells, and effectively suppresses tumour growth in animal models[1].

• Target Antigen:

  Apoptosis; DNA/RNA Synthesis

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/_S_-Crizotinib.html

• Purity:

  99.81

• Solubility:

  DMSO : 12.5 mg/mL (ultrasonic)

• Smiles:

  NC1=NC=C(C2=CN(C3CCNCC3)N=C2)C=C1O[C@H](C4=C(Cl)C=CC(F)=C4Cl)C

• Molecular Weight:

  450.34

• References & Citations:

  [1]Huber KV, et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 2014 Apr 10;508(7495):222-7.|[2]Dai X, et al. (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1. J Exp Clin Cancer Res. 2017 Sep 7;36(1):120.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1374356-45-2